Abstract
Data from patients treated with tenoxicam, a new nonsteroidal anti-inflammatory drug (NSAID), have been collected from patients during the first 2 years of marketing. These data, from 250 million patient-days of tenoxicam use, have confirmed that the efficacy and safety of the drug compares favourably with that shown by other well established NSAIDs in the treatment of rheumatoid arthritis, Osteoarthritis, ankylosing Spondylitis, gout and soft tissue injury/extra-articular inflammatory disease. The once-daily dose of 20mg established in clinical trials has been shown to control pain and inflammation in short term usage as well as in the long term treatment of chronic rheumatic disorders. Several studies in elderly patients have shown that tenoxicam can be safely given at this dose for a longer period of time to patients with mild or moderate renal impairment and that a higher frequency of adverse events is not seen in the elderly patient population.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
